This phase III trial evaluates the effectiveness and safety of using a targeted therapy (Durvalumab), either alone or in combination with another targeted therapy (Bevacizumab), to extend remission in patients who have a high risk of hepatocellular carcinoma recurrence post curative treatment.
This trial is treating patients with Hepatocellular Carcinoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Commercial Sponsor
AstraZeneca
Summary
Patients eligible to participate in this trial will receive intravenous administration of either Durvalumab and Bevacizumab, Durvalumab and a Bevacizumab placebo, or two placebos.
Not Recruiting Hospitals Read More